Serotonin Hypothesis of Autism: Implications for Selective Serotonin Reuptake Inhibitor Use during Pregnancy

Autism Research

Volumn 6, Issue 3, 2013, Pages 149-168

  Harrington, Rebecca A ^a   Lee, Li Ching ^a   Crum, Rosa M ^b   Zimmerman, Andrew W ^c   Hertz Picciotto, Irva ^d  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autism spectrum disorders; Pregnancy; Selective serotonin reuptake inhibitors; Serotonin

Indexed keywords

SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; AUTISM; BRAIN DEVELOPMENT; FIRST TRIMESTER PREGNANCY; HUMAN; NERVE CELL DIFFERENTIATION; PREGNANCY; PRENATAL EXPOSURE; PRIORITY JOURNAL; PUERPERAL DEPRESSION; SEROTONINERGIC SYSTEM;

CHILD DEVELOPMENT DISORDERS, PERVASIVE; DEPRESSIVE DISORDER; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, FIRST; PRENATAL EXPOSURE DELAYED EFFECTS; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 84879217408     PISSN: 19393792     EISSN: 19393806     Source Type: Journal    
DOI: 10.1002/aur.1288     Document Type: Article

References (194)

1. Abbott, N.J., Patabendige, A.A., Dolman, D.E., Yusof, S.R., & Begley, D.J. (2010). Structure and function of the blood-brain barrier. Neurobiology of Disease, 37, 13-25.
2. Abbott, N.J., Ronnback, L., & Hansson, E. (2006). Astrocyte-endothelial interactions at the blood-brain barrier. Nature Reviews. Neuroscience, 7, 41-53.
3. Alwan, S., Reefhuis, J., Rasmussen, S.A., Friedman, J.M., & National Birth Defects Prevention Study. (2011). Patterns of antidepressant medication use among pregnant women in a United States population. Journal of Clinical Pharmacology, 51, 264-270.
4. Alwan, S., Reefhuis, J., Rasmussen, S.A., Olney, R.S., Friedman, J.M., & National Birth Defects Prevention Study. (2007). Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. The New England Journal of Medicine, 356, 2684-2692.
5. Anderson, G.M. (1987). Monoamines in autism: An update of neurochemical research on a pervasive developmental disorder. Medical Biology, 65, 67-74.
6. Anderson, G.M. (2002). Genetics of childhood disorders: XLV. Autism, part 4: Serotonin in autism. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 1513-1516.
7. Anderson, G.M. (2007). Measurement of plasma serotonin in autism. Pediatric Neurology, 36, 138.
8. Anderson, G.M., Czarkowski, K., Ravski, N., & Epperson, C.N. (2004). Platelet serotonin in newborns and infants: Ontogeny, heritability, and effect of in utero exposure to selective serotonin reuptake inhibitors. Pediatric Research, 56, 418-422.
9. Anderson, G.M., Freedman, D.X., Cohen, D.J., Volkmar, F.R., Hoder, E.L., etal. (1987). Whole blood serotonin in autistic and normal subjects. Journal of Child Psychology and Psychiatry, and Allied Disciplines, 28, 885-900.
10. Anderson, G.M., Horne, W.C., Chatterjee, D., & Cohen, D.J. (1990). The hyperserotonemia of autism. Annals of the New York Academy of Sciences, 600, 331-340.
11. Andersson, L., Sundstrom-Poromaa, I., Wulff, M., Astrom, M., & Bixo, M. (2006). Depression and anxiety during pregnancy and six months postpartum: A follow-up study. Acta Obstetricia et Gynecologica Scandinavica, 85, 937-944.
12. Andrade, S.E., McPhillips, H., Loren, D., Raebel, M.A., Lane, K., etal. (2009). Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiology and Drug Safety, 18, 246-252.
13. Andrade, S.E., Raebel, M.A., Brown, J., Lane, K., Livingston, J., etal. (2008). Use of antidepressant medications during pregnancy: A multisite study. American Journal of Obstetrics and Gynecology, 198, 194.e1-194.e5.
14. Ansorge, M.S., Hen, R., & Gingrich, J.A. (2007). Neurodevelopmental origins of depressive disorders. Current Opinion in Pharmacology, 7, 8-17.
15. Arieff, Z., Kaur, M., Gameeldien, H., van der Merwe, L., & Bajic, V.B. (2010). 5-HTTLPR polymorphism: Analysis in South African autistic individuals. Human Biology, 82, 291-300.
16. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators. (2012). Prevalence of autism spectrum disorders-Autism and developmental disabilities monitoring network, 14 sites, United States, 2008. Morbidity and Mortality Weekly Report. Surveillance Summaries, 61, 1-19.
17. Bakker, M.K., Kolling, P., van den Berg, P.B., de Walle, H.E., & de Jong van den Berg, L.T. (2008). Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. British Journal of Clinical Pharmacology, 65, 600-606.
18. Bale, T.L., Baram, T.Z., Brown, A.S., Goldstein, J.M., Insel, T.R., etal. (2010). Early life programming and neurodevelopmental disorders. Biological Psychiatry, 68, 314-319.
19. Balkovetz, D.F., Tiruppathi, C., Leibach, F.H., Mahesh, V.B., & Ganapathy, V. (1989). Evidence for an imipramine-sensitive serotonin transporter in human placental brush-border membranes. The Journal of Biological Chemistry, 264, 2195-2198.
20. Benes, F.M., Taylor, J.B., & Cunningham, M.C. (2000). Convergence and plasticity of monoaminergic systems in the medial prefrontal cortex during the postnatal period: Implications for the development of psychopathology. Cerebral Cortex, 10, 1014-1027.
21. Berger, M., Gray, J.A., & Roth, B.L. (2009). The expanded biology of serotonin. Annual Review of Medicine, 60, 355-366.
22. Betancur, C. (2011). Etiological heterogeneity in autism spectrum disorders: More than 100 genetic and genomic disorders and still counting. Brain Research, 1380, 42-77.
23. Bonari, L., Pinto, N., Ahn, E., Einarson, A., Steiner, M., & Koren, G. (2004). Perinatal risks of untreated depression during pregnancy. Canadian Journal of Psychiatry, 49, 726-735.
24. Bonnin, A., Goeden, N., Chen, K., Wilson, M.L., King, J., etal. (2011). A transient placental source of serotonin for the fetal forebrain. Nature, 472, 347-350.
25. Borue, X., Chen, J., & Condron, B.G. (2007). Developmental effects of SSRIs: Lessons learned from animal studies. International Journal of Developmental Neuroscience, 25, 341-347.
26. Boylan, C.B., Blue, M.E., & Hohmann, C.F. (2007). Modeling early cortical serotonergic deficits in autism. Behavioural Brain Research, 176, 94-108.
27. Brodkin, E.S., McDougle, C.J., Naylor, S.T., Cohen, D.J., & Price, L.H. (1997). Clomipramine in adults with pervasive developmental disorders: A prospective open-label investigation. Journal of Child and Adolescent Psychopharmacology, 7, 109-121.
28. Bromley, R.L., Mawer, G., Clayton-Smith, J., Baker, G.A., & Liverpool and Manchester Neurodevelopment Group. (2008). Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology, 71, 1923-1924.
29. Buie, T., Campbell, D.B., Fuchs, G.J., Furuta, G.T., Levy, J., etal. (2010). Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: A consensus report. Pediatrics, 125(Suppl 1), S1-18.
30. Cabrera-Vera, T.M., Garcia, F., Pinto, W., & Battaglia, G. (2000). Neurochemical changes in brain serotonin neurons in immature and adult offspring prenatally exposed to cocaine. Brain Research, 870, 1-9.
31. Casper, R.C., Fleisher, B.E., Lee-Ancajas, J.C., Gilles, A., Gaylor, E., etal. (2003). Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. The Journal of Pediatrics, 142, 402-408.
32. Casper, R.C., Gilles, A.A., Fleisher, B.E., Baran, J., Enns, G., & Lazzeroni, L.C. (2011). Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: Effects on neonatal adaptation and psychomotor development. Psychopharmacology, 217, 211-219.
33. Caspi, A., Sugden, K., Moffitt, T.E., Taylor, A., Craig, I.W., etal. (2003). Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science, 301, 386-389.
34. Chambers, C.D., Hernandez-Diaz, S., Van Marter, L.J., Werler, M.M., Louik, C., etal. (2006). Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. The New England Journal of Medicine, 354, 579-587.
35. Christensen, H.D., Rayburn, W.F., & Gonzalez, C.L. (2000). Chronic prenatal exposure to paroxetine (Paxil) and cognitive development of mice offspring. Neurotoxicology and Teratology, 22, 733-739.
36. Chugani, D.C., Muzik, O., Behen, M., Rothermel, R., Janisse, J.J., etal. (1999). Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Annals of Neurology, 45, 287-295.
37. Chugani, D.C., Muzik, O., Rothermel, R., Behen, M., Chakraborty, P., etal. (1997). Altered serotonin synthesis in the dentatothalamocortical pathway in autistic boys. Annals of Neurology, 42, 666-669.
38. Cohen, I.L., Liu, X., Lewis, M.E., Chudley, A., Forster-Gibson, C., etal. (2011). Autism severity is associated with child and maternal MAOA genotypes. Clinical Genetics, 79, 355-362.
39. Cohen, I.L., Liu, X., Schutz, C., White, B.N., Jenkins, E.C., etal. (2003). Association of autism severity with a monoamine oxidase A functional polymorphism. Clinical Genetics, 64, 190-197.
40. Cohen, I.L., Tsiouris, J.A., Flory, M.J., Kim, S.Y., Freedland, R., etal. (2010). A large scale study of the psychometric characteristics of the IBR modified overt aggression scale: Findings and evidence for increased self-destructive behaviors in adult females with autism spectrum disorder. Journal of Autism and Developmental Disorders, 40, 599-609.
41. Cohen, L.S., Altshuler, L.L., Harlow, B.L., Nonacs, R., Newport, D.J., etal. (2006). Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA: Journal of the American Medical Association, 295, 499-507.
42. Connors, S.L., Matteson, K.J., Sega, G.A., Lozzio, C.B., Carroll, R.C., & Zimmerman, A.W. (2006). Plasma serotonin in autism. Pediatric Neurology, 35, 182-186.
43. Cook, E.H., & Leventhal, B.L. (1996). The serotonin system in autism. Current Opinion in Pediatrics, 8, 348-354.
44. Cool, D.R., Leibach, F.H., & Ganapathy, V. (1990a). High-affinity paroxetine binding to the human placental serotonin transporter. The American Journal of Physiology, 259(2 Pt 1), C196-C204.
45. Cool, D.R., Liebach, F.H., & Ganapathy, V. (1990b). Interaction of fluoxetine with the human placental serotonin transporter. Biochemical Pharmacology, 40, 2161-2167.
46. Cooper, W.O., Willy, M.E., Pont, S.J., & Ray, W.A. (2007). Increasing use of antidepressants in pregnancy. American Journal of Obstetrics and Gynecology, 196, 544.e1-544.e5.
47. Cote, F., Fligny, C., Bayard, E., Launay, J.M., Gershon, M.D., etal. (2007). Maternal serotonin is crucial for murine embryonic development. Proceedings of the National Academy of Sciences of the United States of America, 104, 329-334.
48. Coutinho, A.M., Sousa, I., Martins, M., Correia, C., Morgadinho, T., etal. (2007). Evidence for epistasis between SLC6A4 and ITGB3 in autism etiology and in the determination of platelet serotonin levels. Human Genetics, 121, 243-256.
49. Croen, L.A., Grether, J.K., Yoshida, C.K., Odouli, R., & Hendrick, V. (2011). Antidepressant use during pregnancy and childhood autism spectrum disorders. Archives of General Psychiatry, 68, 1104-1112.
50. Croonenberghs, J., Verkerk, R., Scharpe, S., Deboutte, D., & Maes, M. (2005). Serotonergic disturbances in autistic disorder: L-5-hydroxytryptophan administration to autistic youngsters increases the blood concentrations of serotonin in patients but not in controls. Life Sciences, 76, 2171-2183.
51. Daneman, R., Zhou, L., Kebede, A.A., & Barres, B.A. (2010). Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature, 468, 562-566.
52. Daubert, E.A., & Condron, B.G. (2010). Serotonin: A regulator of neuronal morphology and circuitry. Trends in Neurosciences, 33, 424-434.
53. Deave, T., Heron, J., Evans, J., & Emond, A. (2008). The impact of maternal depression in pregnancy on early child development. BJOG, 115, 1043-1051.
54. DeLong, R. (2004). Autism and familial major mood disorder: Are they related? The Journal of Neuropsychiatry and Clinical Neurosciences, 16, 199-213.
55. Devlin, B., Cook, Jr., E.H., Coon, H., Dawson, G., Grigorenko, E.L., etal. (2005). Autism and the serotonin transporter: The long and short of it. Molecular Psychiatry, 10, 1110-1116.
56. Dietz, P.M., Williams, S.B., Callaghan, W.M., Bachman, D.J., Whitlock, E.P., & Hornbrook, M.C. (2007). Clinically identified maternal depression before, during, and after pregnancies ending in live births. The American Journal of Psychiatry, 164, 1515-1520.
57. Dufour-Rainfray, D., Vourc'h, P., Tourlet, S., Guilloteau, D., Chalon, S., & Andres, C.R. (2011). Fetal exposure to teratogens: Evidence of genes involved in autism. Neuroscience and Biobehavioral Reviews, 35, 1254-1265.
58. Dunkel Schetter, C., & Tanner, L. (2012). Anxiety, depression and stress in pregnancy: Implications for mothers, children, research, and practice. Current Opinion in Psychiatry, 25, 141-148.
59. Einarson, A., Pistelli, A., DeSantis, M., Malm, H., Paulus, W.D., etal. (2008). Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. The American Journal of Psychiatry, 165, 749-752.
60. Ferreira, E., Carceller, A.M., Agogue, C., Martin, B.Z.S., Andre, M., etal. (2007). Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics, 119, 52-59.
61. Frodl, T., Koutsouleris, N., Bottlender, R., Born, C., Jager, M., etal. (2008). Reduced gray matter brain volumes are associated with variants of the serotonin transporter gene in major depression. Molecular Psychiatry, 13, 1093-1101.
62. Galbally, M., Lewis, A.J., & Buist, A. (2011). Developmental outcomes of children exposed to antidepressants in pregnancy. The Australian and New Zealand Journal of Psychiatry, 45, 393-399.
63. Gaspar, P., Cases, O., & Maroteaux, L. (2003). The developmental role of serotonin: News from mouse molecular genetics. Nature Reviews. Neuroscience, 4, 1002-1012.
64. Gentile, S., & Bellantuono, C. (2009). Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of fetal major malformations: focus on paroxetine. The Journal of Clinical Psychiatry, 70, 414-422.
65. Gentile, S., Rossi, A., & Bellantuono, C. (2007). SSRIs during breastfeeding: Spotlight on milk-to-plasma ratio. Archives of Women's Mental Health, 10, 39-51.
66. Giannaccini, G., Betti, L., Palego, L., Schmid, L., Fabbrini, L., etal. (2010). Human serotonin transporter expression during megakaryocytic differentiation of MEG-01 cells. Neurochemical Research, 35, 628-635.
67. Gillberg, C., & Svennerholm, L. (1987). CSF monoamines in autistic syndromes and other pervasive developmental disorders of early childhood. The British Journal of Psychiatry, 151, 89-94.
68. Greenberg, B.D., Tolliver, T.J., Huang, S.J., Li, Q., Bengel, D., & Murphy, D.L. (1999). Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. American Journal of Medical Genetics, 88, 83-87.
69. Hadjikhani, N. (2010). Serotonin, pregnancy and increased autism prevalence: Is there a link? Medical Hypotheses, 74, 880-883.
70. Hallmayer, J., Cleveland, S., Torres, A., Phillips, J., Cohen, B., etal. (2011). Genetic heritability and shared environmental factors among twin pairs with autism. Archives of General Psychiatry, 68, 1095-1102.
71. Hanley, H.G., Stahl, S.M., & Freedman, D.X. (1977). Hyperserotonemia and amine metabolites in autistic and retarded children. Archives of General Psychiatry, 34, 521-531.
72. Hayes, R.M., Wu, P., Shelton, R.C., Cooper, W.O., Dupont, W.D., etal. (2012). Maternal antidepressant use and adverse outcomes: A cohort study of 228, 876 pregnancies. American Journal of Obstetrics and Gynecology, 207, 49.e1-49.e9.
73. Hedner, J., Lundell, K.H., Breese, G.R., Mueller, R.A., & Hedner, T. (1986). Developmental variations in CSF monoamine metabolites during childhood. Biology of the Neonate, 49, 190-197.
74. Heikkinen, T., Ekblad, U., Kero, P., Ekblad, S., & Laine, K. (2002). Citalopram in pregnancy and lactation. Clinical Pharmacology and Therapeutics, 72, 184-191.
75. Heikkinen, T., Ekblad, U., Palo, P., & Laine, K. (2003). Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clinical Pharmacology and Therapeutics, 73, 330-337.
76. Heils, A., Teufel, A., Petri, S., Stober, G., Riederer, P., etal. (1996). Allelic variation of human serotonin transporter gene expression. Journal of Neurochemistry, 66, 2621-2624.
77. Hendrick, V., Stowe, Z.N., Altshuler, L.L., Hwang, S., Lee, E., & Haynes, D. (2003). Placental passage of antidepressant medications. The American Journal of Psychiatry, 160, 993-996.
78. Hertz-Picciotto, I., & Delwiche, L. (2009). The rise in autism and the role of age at diagnosis. Epidemiology, 20, 84-90.
79. Hiemke, C., & Hartter, S. (2000). Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacology & Therapeutics, 85, 11-28.
80. Hilton, C.L., Zhang, Y., White, M.R., Klohr, C.L., & Constantino, J. (2012). Motor impairment in sibling pairs concordant and discordant for autism spectrum disorders. Autism: The International Journal of Research and Practice, 16, 430-441.
81. Hollander, E., Phillips, A., Chaplin, W., Zagursky, K., Novotny, S., etal. (2005). A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology, 30, 582-589.
82. Hollander, E., Soorya, L., Chaplin, W., Anagnostou, E., Taylor, B.P., etal. (2012). A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. The American Journal of Psychiatry, 169, 292-299.
83. Homberg, J.R., Schubert, D., & Gaspar, P. (2010). New perspectives on the neurodevelopmental effects of SSRIs. Trends in Pharmacological Sciences, 31, 60-65.
84. Hranilovic, D., Bujas-Petkovic, Z., Vragovic, R., Vuk, T., Hock, K., & Jernej, B. (2007). Hyperserotonemia in adults with autistic disorder. Journal of Autism and Developmental Disorders, 37, 1934-1940.
85. Hranilovic, D., Novak, R., Babic, M., Novokmet, M., Bujas-Petkovic, Z., & Jernej, B. (2008). Hyperserotonemia in autism: The potential role of 5HT-related gene variants. Collegium Antropologicum, 32(Suppl 1), 75-80.
86. Il'kova, G., Rehak, P., Vesela, J., Cikos, S., Fabian, D., etal. (2004). Serotonin localization and its functional significance during mouse preimplantation embryo development. Zygote, 12, 205-213.
87. Johansson, P.A., Dziegielewska, K.M., Liddelow, S.A., & Saunders, N.R. (2008). The blood-CSF barrier explained: When development is not immaturity. BioEssays: News and Reviews in Molecular, Cellular and Developmental Biology, 30, 237-248.
88. Kallen, B., & Olausson, P.O. (2008). Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiology and Drug Safety, 17, 801-806.
89. Kieler, H., Artama, M., Engeland, A., Ericsson, O., Furu, K., etal. (2011). Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: Population based cohort study from the five Nordic countries. BMJ (Clinical Research Ed.), 344, d8012.
90. Kim, C.S., McNamara, M.C., Lauder, J.M., & Lawson, E.E. (1994). Immunocytochemical detection of serotonin content in raphé neurons of newborn and young adult rabbits before and after acute hypoxia. International Journal of Developmental Neuroscience, 12, 499-505.
91. King, B.H., Hollander, E., Sikich, L., McCracken, J.T., Scahill, L., etal. (2009). Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: Citalopram ineffective in children with autism. Archives of General Psychiatry, 66, 583-590.
92. Kistner-Griffin, E., Brune, C.W., Davis, L.K., Sutcliffe, J.S., Cox, N.J., & Cook, Jr., E.H. (2011). Parent-of-origin effects of the serotonin transporter gene associated with autism. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 156, 139-144.
93. Kontur, P.J., Leranth, C., Redmond, Jr., D.E., Roth, R.H., & Robbins, R.J. (1993). Tyrosine hydroxylase immunoreactivity and monoamine and metabolite levels in cryopreserved human fetal ventral mesencephalon. Experimental Neurology, 121, 172-180.
94. Krakowiak, P., Goodlin-Jones, B., Hertz-Picciotto, I., Croen, L.A., & Hansen, R.L. (2008). Sleep problems in children with autism spectrum disorders, developmental delays, and typical development: A population-based study. Journal of Sleep Research, 17, 197-206.
95. Larson, M.J., Miller, K., & Fleming, K.J. (2007). Treatment with antidepressant medications in private health plans. Administration and Policy in Mental Health, 34, 116-126.
96. Leboyer, M., Philippe, A., Bouvard, M., Guilloud-Bataille, M., Bondoux, D., etal. (1999). Whole blood serotonin and plasma beta-endorphin in autistic probands and their first-degree relatives. Biological Psychiatry, 45, 158-163.
97. Levallois, C., Valence, C., Baldet, P., & Privat, A. (1997). Morphological and morphometric analysis of serotonin-containing neurons in primary dissociated cultures of human rhombencephalon: A study of development. Brain Research. Developmental Brain Research, 99, 243-252.
98. Levin, M., Buznikov, G.A., & Lauder, J.M. (2006). Of minds and embryos: Left-right asymmetry and the serotonergic controls of pre-neural morphogenesis. Developmental Neuroscience, 28, 171-185.
99. Lisboa, S.F., Oliveira, P.E., Costa, L.C., Venancio, E.J., & Moreira, E.G. (2007). Behavioral evaluation of male and female mice pups exposed to fluoxetine during pregnancy and lactation. Pharmacology, 80, 49-56.
100. Longo, D., Schuler-Faccini, L., Brandalize, A.P., dos Santos Riesgo, R., & Bau, C.H. (2009). Influence of the 5-HTTLPR polymorphism and environmental risk factors in a Brazilian sample of patients with autism spectrum disorders. Brain Research, 1267, 9-17.
101. Lorenzo, L., Byers, B., & Einarson, A. (2011). Antidepressant use in pregnancy. Expert Opinion on Drug Safety, 10, 883-889.
102. Loughhead, A.M., Fisher, A.D., Newport, D.J., Ritchie, J.C., Owens, M.J., etal. (2006). Antidepressants in amniotic fluid: Another route of fetal exposure. The American Journal of Psychiatry, 163, 145-147.
103. Louik, C., Lin, A.E., Werler, M.M., Hernandez-Diaz, S., & Mitchell, A.A. (2007). First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. The New England Journal of Medicine, 356, 2675-2683.
104. Maimburg, R.D., & Vaeth, M. (2006). Perinatal risk factors and infantile autism. Acta Psychiatrica Scandinavica, 114, 257-264.
105. Malm, H., Artama, M., Gissler, M., & Ritvanen, A. (2011). Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstetrics and Gynecology, 118, 111-120.
106. Marazziti, D., Muratori, F., Cesari, A., Masala, I., Baroni, S., etal. (2000). Increased density of the platelet serotonin transporter in autism. Pharmacopsychiatry, 33, 165-168.
107. Mattson, S.N., Eastvold, A.D., Jones, K.L., Harris, J.A., & Chambers, C.D. (1999). Neurobehavioral follow-up of children prenatally exposed to fluoxetine [Abstract]. Teratology, 59, 376.
108. McAllister, B.B., Kiryanova, V., & Dych, R.H. (2012). Behavioural outcomes of perinatal maternal fluoxetine treatment. Neuroscience, 226, 356-366.
109. McBride, P.A., Anderson, G.M., Hertzig, M.E., Snow, M.E., Thompson, S.M., etal. (1998). Effects of diagnosis, race, and puberty on platelet serotonin levels in autism and mental retardation. Journal of the American Academy of Child and Adolescent Psychiatry, 37, 767-776.
110. McDougle, C.J., Naylor, S.T., Cohen, D.J., Aghajanian, G.K., Heninger, G.R., & Price, L.H. (1996a). Effects of tryptophan depletion in drug-free adults with autistic disorder. Archives of General Psychiatry, 53, 993-1000.
111. McDougle, C.J., Naylor, S.T., Cohen, D.J., Volkmar, F.R., Heninger, G.R., & Price, L.H. (1996b). A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry, 53, 1001-1008.
112. Melke, J., Goubran Botros, H., Chaste, P., Betancur, C., Nygren, G., etal. (2008). Abnormal melatonin synthesis in autism spectrum disorders. Molecular Psychiatry, 13, 90-98.
113. Meredith, E.J., Chamba, A., Holder, M.J., Barnes, N.M., & Gordon, J. (2005). Close encounters of the monoamine kind: Immune cells betray their nervous disposition. Immunology, 115, 289-295.
114. Meyer, J.H., Wilson, A.A., Ginovart, N., Goulding, V., Hussey, D., etal. (2001). Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: A [(11)C]DASB PET imaging study. The American Journal of Psychiatry, 158, 1843-1849.
115. Meyer, J.H., Wilson, A.A., Sagrati, S., Hussey, D., Carella, A., etal. (2004). Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: An [11C]DASB positron emission tomography study. The American Journal of Psychiatry, 161, 826-835.
116. Misri, S., Reebye, P., Kendrick, K., Carter, D., Ryan, D., etal. (2006). Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. The American Journal of Psychiatry, 163, 1026-1032.
117. Mojtabai, R., & Olfson, M. (2011). Proportion of antidepressants prescribed without a psychiatric diagnosis is growing. Health Affairs, 30, 1434-1442.
118. Morison, S.J., Grunau, R.E., Oberlander, T.F., Misri, S., Pannikar, H., & Reebye, P. (2001). Infant social behavior and development in the first year of life following prolonged prenatal psychotropic medication exposure [Abstract]. Pediatric Research, 49(4 Pt 2 Suppl), 28A.
119. Mortensen, J.T., Olsen, J., Larsen, H., Bendsen, J., Obel, C., & Sorensen, H.T. (2003). Psychomotor development in children exposed in utero to benzodiazepines, antidepressants, neuroleptics, and anti-epileptics. European Journal of Epidemiology, 18, 769-771.
120. Moses-Kolko, E.L., Bogen, D., Perel, J., Bregar, A., Uhl, K., etal. (2005). Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: Literature review and implications for clinical applications. JAMA: the Journal of the American Medical Association, 293, 2372-2383.
121. Mulder, E.J., Anderson, G.M., Kema, I.P., de Bildt, A., van Lang, N.D., etal. (2004). Platelet serotonin levels in pervasive developmental disorders and mental retardation: Diagnostic group differences, within-group distribution, and behavioral correlates. Journal of the American Academy of Child and Adolescent Psychiatry, 43, 491-499.
122. Muneoka, K., Ogawa, T., Kamei, K., Muraoka, S., Tomiyoshi, R., etal. (1997). Prenatal nicotine exposure affects the development of the central serotonergic system as well as the dopaminergic system in rat offspring: Involvement of route of drug administrations. Brain Research. Developmental Brain Research, 102, 117-126.
123. Nakhai-Pour, H.R., Broy, P., & Berard, A. (2010). Use of antidepressants during pregnancy and the risk of spontaneous abortion. CMAJ: Canadian Medical Association Journal, 182, 1031-1037.
124. Narayan, M., Srinath, S., Anderson, G.M., & Meundi, D.B. (1993). Cerebrospinal fluid levels of homovanillic acid and 5-hydroxyindoleacetic acid in autism. Biological Psychiatry, 33, 630-635.
125. Nordeng, H., van Gelder, M.M., Spigset, O., Koren, G., Einarson, A., & Eberhard-Gran, M. (2012). Pregnancy outcome after exposure to antidepressants and the role of maternal depression: Results from the Norwegian mother and child cohort study. Journal of Clinical Psychopharmacology, 32, 186-194.
126. Nordquist, N., & Oreland, L. (2010). Serotonin, genetic variability, behaviour, and psychiatric disorders-A review. Upsala Journal of Medical Sciences, 115, 2-10.
127. Nulman, I., Rovet, J., Stewart, D.E., Wolpin, J., Gardner, H.A., etal. (1997). Neurodevelopment of children exposed in utero to antidepressant drugs. The New England Journal of Medicine, 336, 258-262.
128. Nulman, I., Rovet, J., Stewart, D.E., Wolpin, J., Pace-Asciak, P., etal. (2002). Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: A prospective, controlled study. The American Journal of Psychiatry, 159, 1889-1895.
129. Oberlander, T.F., Gingrich, J.A., & Ansorge, M.S. (2009). Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: Molecular to clinical evidence. Clinical Pharmacology and Therapeutics, 86, 672-677.
130. Oberlander, T.F., Misri, S., Fitzgerald, C.E., Kostaras, X., Rurak, D., & Riggs, W. (2004). Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. The Journal of Clinical Psychiatry, 65, 230-237.
131. Oberlander, T.F., Papsdorf, M., Brain, U.M., Misri, S., Ross, C., & Grunau, R.E. (2010). Prenatal effects of selective serotonin reuptake inhibitor antidepressants, serotonin transporter promoter genotype (SLC6A4), and maternal mood on child behavior at 3 years of age. Archives of Pediatrics & Adolescent Medicine, 164, 444-451.
132. Oberlander, T.F., Reebye, P., Misri, S., Papsdorf, M., Kim, J., & Grunau, R.E. (2007). Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Archives of Pediatrics & Adolescent Medicine, 161, 22-29.
133. Olivier, J.D., Blom, T., Arentsen, T., & Homberg, J.R. (2011). The age-dependent effects of selective serotonin reuptake inhibitors in humans and rodents: A review. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 35, 1400-1408.
134. Pastuszak, A., Schick-Boschetto, B., Zuber, C., Feldkamp, M., Pinelli, M., etal. (1993). Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA: the Journal of the American Medical Association, 269, 2246-2248.
135. Pedersen, L.H., Henriksen, T.B., & Olsen, J. (2010). Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics, 125, e600-e608.
136. Petersen, I., Gilbert, R.E., Evans, S.J., Man, S.L., & Nazareth, I. (2011). Pregnancy as a major determinant for discontinuation of antidepressants: An analysis of data from the health improvement network. The Journal of Clinical Psychiatry, 72, 979-985.
137. Piven, J., & Palmer, P. (1999). Psychiatric disorder and the broad autism phenotype: Evidence from a family study of multiple-incidence autism families. The American Journal of Psychiatry, 156, 557-563.
138. Preskorn, S.H. (2012). The use of biomarkers in psychiatric research: How serotonin transporter occupancy explains the dose-response curves of SSRIs. Journal of Psychiatric Practice, 18, 38-45.
139. Preskorn, S.H., Ross, R., & Stanga, C.Y. (2004). Selective serotonin reuptake inhibitors. In S.H. Preskorn, J.P. Feighner, C.Y. Stanga, & R. Ross (Eds.), Antidepressants: Past, present and future (pp. 242-262). Berlin, Germany: Springer.
140. Pytliak, M., Vargova, V., Mechirova, V., & Felsoci, M. (2011). Serotonin receptors-From molecular biology to clinical applications. Physiological Research, 60, 15-25.
141. Ramoz, N., Reichert, J.G., Corwin, T.E., Smith, C.J., Silverman, J.M., etal. (2006). Lack of evidence for association of the serotonin transporter gene SLC6A4 with autism. Biological Psychiatry, 60, 186-191.
142. Rampono, J., Simmer, K., Ilett, K.F., Hackett, L.P., Doherty, D.A., etal. (2009). Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry, 42, 95-100.
143. Rayen, I., van den Hove, D.L., Prickaerts, J., Steinbusch, H.W., & Pawluski, J.L. (2011). Fluoxetine during development reverses the effects of prenatal stress on depressive-like behavior and hippocampal neurogenesis in adolescence. PLoS ONE, 6, e24003.
144. Reebye, P., Morison, S.J., Panikkar, H., Misri, S., & Grunau, R.E. (2002). Affect expression in prenatally psychotropic exposed and nonexposed mother-infant dyads. Infant Mental Health Journal, 23, 403-416.
145. Reefhuis, J., Rasmussen, S.A., & Friedman, J.M. (2006). Selective serotonin-reuptake inhibitors and persistent pulmonary hypertension of the newborn. The New England Journal of Medicine, 354, 2188-2190.
146. Rice, C., Nicholas, J., Baio, J., Pettygrove, S., Lee, L.C., etal. (2010). Changes in autism spectrum disorder prevalence in 4 areas of the United States. Disability and Health Journal, 3, 186-201.
147. Romijn, H.J., Hofman, M.A., & Gramsbergen, A. (1991). At what age is the developing cerebral cortex of the rat comparable to that of the full-term newborn human baby? Early Human Development, 26, 61-67.
148. Rurak, D., Lim, K., Sanders, A., Brain, U., Riggs, W., & Oberlander, T.F. (2011). Third trimester fetal heart rate and Doppler middle cerebral artery blood flow velocity characteristics during prenatal selective serotonin reuptake inhibitor exposure. Pediatric Research, 70, 96-101.
149. Sabol, S.Z., Hu, S., & Hamer, D. (1998). A functional polymorphism in the monoamine oxidase A gene promoter. Human Genetics, 103, 273-279.
150. Sari, Y., Powrozek, T., & Zhou, F.C. (2001). Alcohol deters the outgrowth of serotonergic neurons at midgestation. Journal of Biomedical Science, 8, 119-125.
151. Schain, R.J., & Freedman, D.X. (1961). Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. The Journal of Pediatrics, 58, 315-320.
152. Schmidt, R.J., Hansen, R.L., Hartiala, J., Allayee, H., Schmidt, L.C., etal. (2011). Prenatal vitamins, one-carbon metabolism gene variants, and risk for autism. Epidemiology, 22, 476-485.
153. Schmidt, R.J., Tancredi, D.J., Ozonoff, S., Hansen, R.L., Hartiala, J., etal. (2012). Maternal periconceptional folic acid intake and risk of autism spectrum disorders and developmental delay in the CHARGE (Childhood autism risks from genetics and environment) case-control study. The American Journal of Clinical Nutrition, 96, 80-89.
154. Serfaty, C.A., Oliveira-Silva, P., Faria Melibeu Ada, C., & Campello-Costa, P. (2008). Nutritional tryptophan restriction and the role of serotonin in development and plasticity of central visual connections. Neuroimmunomodulation, 15, 170-175.
155. Shen, W.Z., Luo, Z.B., Zheng, D.R., & Yew, D.T. (1989). Immunohistochemical studies on the development of 5-HT (serotonin) neurons in the nuclei of the reticular formations of human fetuses. Pediatric Neuroscience, 15, 291-295.
156. Simon, G.E., Cunningham, M.L., & Davis, R.L. (2002). Outcomes of prenatal antidepressant exposure. The American Journal of Psychiatry, 159, 2055-2061.
157. Simonoff, E., Pickles, A., Charman, T., Chandler, S., Loucas, T., & Baird, G. (2008). Psychiatric disorders in children with autism spectrum disorders: Prevalence, comorbidity, and associated factors in a population-derived sample. Journal of the American Academy of Child and Adolescent Psychiatry, 47, 921-929.
158. Sivasubramaniam, S.D., Finch, C.C., Billett, M.A., Baker, P.N., & Billett, E.E. (2002). Monoamine oxidase expression and activity in human placentae from pre-eclamptic and normotensive pregnancies. Placenta, 23, 163-171.
159. Spence, S.J., & Schneider, M.T. (2009). The role of epilepsy and epileptiform EEGs in autism spectrum disorders. Pediatric Research, 65, 599-606.
160. Stankovski, L., Alvarez, C., Ouimet, T., Vitalis, T., El-Hachimi, K.H., etal. (2007). Developmental cell death is enhanced in the cerebral cortex of mice lacking the brain vesicular monoamine transporter. The Journal of Neuroscience, 27, 1315-1324.
161. Stone, K.J., Viera, A.J., & Parman, C.L. (2003). Off-label applications for SSRIs. American Family Physician, 68, 498-504.
162. Stromland, K., Nordin, V., Miller, M., Akerstrom, B., & Gillberg, C. (1994). Autism in thalidomide embryopathy: A population study. Developmental Medicine and Child Neurology, 36, 351-356.
163. Sundstrom, E., Kolare, S., Souverbie, F., Samuelsson, E.B., Pschera, H., etal. (1993). Neurochemical differentiation of human bulbospinal monoaminergic neurons during the first trimester. Developmental Brain Research, 75, 1-12.
164. Suri, R., Altshuler, L., Hellemann, G., Burt, V.K., Aquino, A., & Mintz, J. (2007). Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. The American Journal of Psychiatry, 164, 1206-1213.
165. Suri, R., Altshuler, L., Hendrick, V., Rasgon, N., Lee, E., & Mintz, J. (2004). The impact of depression and fluoxetine treatment on obstetrical outcome. Archives of Women's Mental Health, 7, 193-200.
166. Suri, R., Hellemann, G., Stowe, Z.N., Cohen, L.S., Aquino, A., & Altshuler, L.L. (2011). A prospective, naturalistic, blinded study of early neurobehavioral outcomes for infants following prenatal antidepressant exposure. The Journal of Clinical Psychiatry, 72, 1002-1007.
167. Szatmari, P. (2011). Is autism, at least in part, a disorder of fetal programming? Archives of General Psychiatry, 68, 1091-1092.
168. Takahashi, H., Nakashima, S., Ohama, E., Takeda, S., & Ikuta, F. (1986). Distribution of serotonin-containing cell bodies in the brainstem of the human fetus determined with immunohistochemistry using antiserotonin serum. Brain & Development, 8, 355-365.
169. Tassone, F., Qi, L., Zhang, W., Hansen, R.L., Pessah, I.N., & Hertz-Picciotto, I. (2011). MAOA, DBH, and SLC6A4 variants in CHARGE: A case-control study of autism spectrum disorders. Autism Research, 4, 250-261.
170. Tordjman, S., Gutknecht, L., Carlier, M., Spitz, E., Antoine, C., etal. (2001). Role of the serotonin transporter gene in the behavioral expression of autism. Molecular Psychiatry, 6, 434-439.
171. Toth, G., & Fekete, M. (1986). 5-hydroxyindole acetic excretion in newborns, infants and children. Acta Paediatrica Hungarica, 27, 221-226.
172. Udechuku, A., Nguyen, T., Hill, R., & Szego, K. (2010). Antidepressants in pregnancy: A systematic review. The Australian and New Zealand Journal of Psychiatry, 44, 978-996.
173. US Food and Drug Administration. (2005). FDA public health advisory: paroxetine. Retrieved September 19, 2011, from http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm051731.htm
174. US Food and Drug Administration. (2006). FDA public health advisory: Treatment challenges of depression in pregnancy and the possibility of persistent pulmonary hypertension in newborns. Retrieved September 19, 2011, from http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm124348.htm
175. Vitalis, T., Cases, O., Passemard, S., Callebert, J., & Parnavelas, J.G. (2007). Embryonic depletion of serotonin affects cortical development. The European Journal of Neuroscience, 26, 331-344.
176. Walther, D.J., Peter, J.U., Bashammakh, S., Hortnagl, H., Voits, M., etal. (2003). Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science, 299, 76.
177. Weikum, W.M., Oberlander, T.F., Hensch, T.K., & Werker, J.F. (2012). Prenatal exposure to antidepressants and depressed maternal mood alter trajectory of infant speech perception. Proceedings of the National Academy of Sciences of the United States of America, 109(Suppl 2), 17221-17227.
178. Whitaker-Azmitia, P.M. (1998). Role of the neurotrophic properties of serotonin in the delay of brain maturation induced by cocaine. Annals of the New York Academy of Sciences, 846, 158-164.
179. Whitaker-Azmitia, P.M. (2001). Serotonin and brain development: Role in human developmental diseases. Brain Research Bulletin, 56, 479-485.
180. Whitaker-Azmitia, P.M. (2005). Behavioral and cellular consequences of increasing serotonergic activity during brain development: A role in autism? International Journal of Developmental Neuroscience, 23, 75-83.
181. Whitaker-Azmitia, P.M., Druse, M., Walker, P., & Lauder, J.M. (1996). Serotonin as a developmental signal. Behavioural Brain Research, 73, 19-29.
182. Whitaker-Azmitia, P.M., Zhang, X., & Clarke, C. (1994). Effects of gestational exposure to monoamine oxidase inhibitors in rats: Preliminary behavioral and neurochemical studies. Neuropsychopharmacology, 11, 125-132.
183. White, K.J., Walline, C.C., & Barker, E.L. (2005). Serotonin transporters: implications for antidepressant drug development. The AAPS Journal, 7, E421-E433.
184. Wichman, C.L., Moore, K.M., Lang, T.R., St Sauver, J.L., Heise, Jr., R.H., & Watson, W.J. (2009). Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clinic Proceedings, 84, 23-27.
185. Williams, K., Wheeler, D.M., Silove, N., & Hazell, P. (2010). Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews (Online) (8), CD004677.
186. Williams, P.G., & Hersh, J.H. (1997). A male with fetal valproate syndrome and autism. Developmental Medicine and Child Neurology, 39, 632-634.
187. Wilson, K.L., Zelig, C.M., Harvey, J.P., Cunningham, B.S., Dolinsky, B.M., & Napolitano, P.G. (2011). Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. American Journal of Perinatology, 28, 19-24.
188. Winter, C., Reutiman, T.J., Folsom, T.D., Sohr, R., Wolf, R.J., etal. (2008). Dopamine and serotonin levels following prenatal viral infection in mouse-implications for psychiatric disorders such as schizophrenia and autism. European Neuropsychopharmacology, 18, 712-716.
189. Wisner, K.L., Sit, D.K., Hanusa, B.H., Moses-Kolko, E.L., Bogen, D.L., etal. (2009). Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. The American Journal of Psychiatry, 166, 557-566.
190. Xu, Y., Sari, Y., & Zhou, F.C. (2004). Selective serotonin reuptake inhibitor disrupts organization of thalamocortical somatosensory barrels during development. Brain Research. Developmental Brain Research, 150, 151-161.
191. Yonkers, K.A., Gotman, N., Smith, M.V., Forray, A., Belanger, K., etal. (2011). Does antidepressant use attenuate the risk of a major depressive episode in pregnancy? Epidemiology, 22, 848-854.
192. Yonkers, K.A., Wisner, K.L., Stewart, D.E., Oberlander, T.F., Dell, D.L., etal. (2009). The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstetrics and Gynecology, 114, 703-713.
193. Yoo, H.J., Lee, S.K., Park, M., Cho, I.H., Hyun, S.H., etal. (2009). Family- and population-based association studies of monoamine oxidase A and autism spectrum disorders in Korean. Neuroscience Research, 63, 172-176.
194. Zhang, X., Beaulieu, J.M., Sotnikova, T.D., Gainetdinov, R.R., & Caron, M.G. (2004). Tryptophan hydroxylase-2 controls brain serotonin synthesis. Science, 305, 217.